Literature DB >> 24668283

Returning to tricyclic antidepressants for depression during childbearing: clinical and dosing challenges.

Lauren M Osborne1, Catherine A Birndorf, Lauren E Szkodny, Katherine L Wisner.   

Abstract

Managing depression and anxiety during pregnancy and the postpartum period is challenging. Both pharmacological treatment and the lack thereof can pose threats to a fetus. SSRIs are the drugs of choice for use during pregnancy, but there is considerable evidence for the safety and efficacy of older antidepressants during pregnancy as well. This study highlights a single case of the use of the tricyclic nortriptyline during pregnancy and postpartum. The subject involved had an unexpectedly high ratio of serum level to drug dose during the postpartum period. We monitored the subject for a significantly greater portion of the postpartum period than has been done in previous studies, and explored medical and lifestyle changes that could account for the level-to-dose ratios we observed. Differences in smoking patterns, coupled with the patient's status as a genetic poor metabolizer, were the most likely explanations.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24668283      PMCID: PMC4116330          DOI: 10.1007/s00737-014-0421-z

Source DB:  PubMed          Journal:  Arch Womens Ment Health        ISSN: 1434-1816            Impact factor:   3.633


  42 in total

1.  Balancing risks: dosing strategies for antidepressants near the end of pregnancy.

Authors:  Laura J Miller; Jeffrey R Bishop; James H Fischer; Stacie E Geller; Carol Macmillan
Journal:  J Clin Psychiatry       Date:  2008-02       Impact factor: 4.384

2.  Induction of CYP2D6 in pregnancy.

Authors:  M Wadelius; E Darj; G Frenne; A Rane
Journal:  Clin Pharmacol Ther       Date:  1997-10       Impact factor: 6.875

3.  Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective, controlled study.

Authors:  Irena Nulman; Joanne Rovet; Donna E Stewart; Jacob Wolpin; Pia Pace-Asciak; Samar Shuhaiber; Gideon Koren
Journal:  Am J Psychiatry       Date:  2002-11       Impact factor: 18.112

4.  Quantitative pharmacogenetics of nortriptyline: a novel approach.

Authors:  E E Kvist; A Al-Shurbaji; M L Dahl; C Nordin; G Alván; L Ståhle
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 5.  Depression during pregnancy: diagnosis and treatment options.

Authors:  Ruta Nonacs; Lee S Cohen
Journal:  J Clin Psychiatry       Date:  2002       Impact factor: 4.384

Review 6.  Antepartum and postpartum depression.

Authors:  M G Spinelli
Journal:  J Gend Specif Med       Date:  1998 Oct-Nov

Review 7.  Nortriptyline pharmacokinetics and plasma levels: implications for clinical practice.

Authors:  E H Rubin; J T Biggs; S H Preskorn
Journal:  J Clin Psychiatry       Date:  1985-10       Impact factor: 4.384

8.  Changes in antidepressant metabolism and dosing across pregnancy and early postpartum.

Authors:  Dorothy K Sit; James M Perel; Joseph C Helsel; Katherine L Wisner
Journal:  J Clin Psychiatry       Date:  2008-04       Impact factor: 4.384

9.  Folate, vitamin B12, homocysteine, and the MTHFR 677C->T polymorphism in anxiety and depression: the Hordaland Homocysteine Study.

Authors:  Ingvar Bjelland; Grethe S Tell; Stein Emil Vollset; Helga Refsum; Per Magne Ueland
Journal:  Arch Gen Psychiatry       Date:  2003-06

10.  Depressive symptoms among pregnant women screened in obstetrics settings.

Authors:  Sheila M Marcus; Heather A Flynn; Frederic C Blow; Kristen L Barry
Journal:  J Womens Health (Larchmt)       Date:  2003-05       Impact factor: 2.681

View more
  1 in total

1.  Selective serotonin reuptake inhibitors and venlafaxine in pregnancy: Changes in drug disposition.

Authors:  Andreas Austgulen Westin; Malin Brekke; Espen Molden; Eirik Skogvoll; Olav Spigset
Journal:  PLoS One       Date:  2017-07-14       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.